Revolutionary faecal transplants are the latest new treatment option being trialled in people living with Parkinson’s to help manage their debilitating symptoms by replenishing their healthy gut bacteria.
The trial is the result of an exciting collaboration between leading Australian biotechnology company BiomeBank, the Departments of Neurology, Nuclear Medicine and Gastroenterology within the Royal Adelaide and Queen Elizabeth hospitals; and The Hospital Research Foundation (THRF) Group.
There has been increasing evidence showing the link between Parkinson’s and gut health. Constipation affects 90 per cent of people living with Parkinson’s, and recent research has also indicated the microbiome within the gut may influence the response to existing therapies for the disease.
BiomeBank is world-leading for its cutting-edge science, innovative technologies and drug manufacturing capabilities, developing microbial therapies with the potential to offer world-first treatments for a number of diseases. The company’s first drug product is already being used throughout Australia to treat the debilitating gut condition Clostridioides difficile (C-diff) through faecal microbiota transplantation (FMT).
Leading Adelaide businessman Kevin Weeks is financially backing the trial, through The Hospital Research Foundation Group. Living with Parkinson’s himself and on the Board of THRF Group charity Parkinson’s SA, Kevin knows how living with the daily symptoms of Parkinson’s can affect people’s quality of life.
People living with Parkinson’s are being sought to participate in the trial, where they’ll be provided with a six-month course of FMT from BiomeBank.
If you would like to participate, you must have a confirmed diagnosis of idiopathic Parkinson’s, receiving levodopa therapy and experiencing a fluctuating response to levodopa. Please contact Dr Michele De Sciscio during business hours via phone 0422 447 902 or email email@example.com for more information and to register your interest.
BiomeBank is a clinical stage biotechnology company developing a pipeline of live biotherapeutic products to treat unmet medical need. BiomeBank’s mission is to treat and prevent disease by replenishing gut microbial ecology.
Currently undertaking its Series-A funding round and attracting local and international investors, BiomeBank was founded by Adelaide gastroenterologist Dr Sam Costello and Dr Rob Bryant, boosted by seed funding from The Hospital Research Foundation Group.
About The Hospital Research Foundation Group
The Hospital Research Foundation Group’s purpose is to ‘together, fight’ for better health and wellbeing for our community through life-changing medical research and improved healthcare. Together with THRF Group charity Parkinson’s SA, it helps improve support, wellbeing services and research for over 8,000 people living with Parkinson’s disease and other movement disorders, their carers, family, community and health professionals.